JUPR NEURPAR Stock

JUNS

US48208B3024

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-07 EDT			5-day change	1st Jan Change
5.100 ^USD	-9.45%		-24.44%	-93.33%

07-21	Jupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million	MT
06-30	Jupiter Neurosciences, Inc. Appoints Tomas J. Philipson as Member of Board and Audit Committee and Compensation Committee, Effective June 26, 2026	CI

Analysts' recommendations: JUPR NEURPAR

25-10-27

Jupiter Neurosciences Signs Up to $20 Million Financing Deals With Yorkville Advisors Global

More recommendations

Managers and Directors: JUPR NEURPAR

Manager	Title	Age	Since
Alexander Rosén ADM	Chief Administrative Officer	34	2015-12-31
Marshall Hayward CTO	Chief Tech/Sci/R&D Officer	71	2015-12-31
Christer Rosén CEO	Chief Executive Officer	74	2015-12-31

Director	Title	Age	Since
Christer Rosén CHM	Chairman	74	2015-12-31
Marshall Hayward BRD	Director/Board Member	71	2015-12-31
Alison Silva BRD	Director/Board Member	48	2017-12-31

More insiders

Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL - a proprietary, enhanced-bioavailability resveratrol formulation - is in a Phase IIa clinical trial for Parkinson's disease. The JOTROL delivery platform allows resveratrol to be consumed in an easily consumable, oral softgel in a patented micellar form. Delivered via the JOTROL platform, resveratrol infuses blood plasma and the central nervous system, and crosses the blood brain barrier, unlocking the compound's potential as a therapeutic for neurodegenerative and neurological diseases, without the GI issues. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a softgel capsule. The Company also commercializes Nugevia, a consumer longevity supplement. It also has rights in ALA-002.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-08-07	US$5.100	-9.45%	119,178
26-08-06	US$5.633	-2.47%	19,227
26-08-05	US$5.775	-25.68%	88,619
26-08-04	US$7.770	+3.60%	42,082
26-08-03	US$7.500	+11.11%	168,522

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	2.95M 2.55M 2.39M 2.19M 4.12M 281M 4.18M 27.98M 10.98M 141M 11.09M 10.85M 466M	P/E 2024	-126x	P/E 2025	-4.08x
Enterprise Value	4.48M 3.88M 3.62M 3.32M 6.25M 427M 6.35M 42.48M 16.68M 214M 16.83M 16.47M 707M	EV / Sales 2024	-	EV / Sales 2025	1,681x
Free-Float	-	Yield 2024 *	-	Yield 2025	-

07-21	Jupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million	MT
06-30	Jupiter Neurosciences, Inc. Appoints Tomas J. Philipson as Member of Board and Audit Committee and Compensation Committee, Effective June 26, 2026	CI
06-29	Top Premarket Decliners	MT
06-22	Jupiter Neurosciences, Inc. Announces Allison W. Brady Decides to Resign from Board, Audit Committee and Compensation Committee, Effective June 17, 2026	CI
05-27	Jupiter Neurosciences, Inc. Announces Patient Enrollment Underway in Phase 2A Reset Trial in Parkinson's Disease	CI
05-27	Jupiter Neurosciences says patient enrollment underway in phase 2a reset trial in Parkinson's disease	RE
05-14	Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-07	Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board	CI
04-01	Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-12	B2i Digital, Inc. Selects Jupiter Neurosciences, Inc. as a B2i Digital Featured Company	CI
01-28	Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users	CI
01-28	Jupiter Neurosciences expands Nugevia addressable market with focus on GLP-1 users	RE

08-05	Jupiter Neurosciences, Inc. Announces Reverse Stock Split	AQ
07-22	Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million	AQ
07-21	Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million	AQ
07-07	Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson	AQ
05-27	Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease	AQ

1 day	-9.45%
1 week	-24.44%
Current month	-24.44%
1 month	-64.73%
3 months	-79.57%
6 months	-88.66%
Current year	-93.33%

1 week	4.76	8.25
1 month	4.76	17.91
Current year	4.76	81.75
1 year	4.76	137.96
3 years	4.76	1,463.25
5 years	4.76	1,463.25
10 years	4.76	1,463.25

JUPR NEURPAR Stock

Stocks

JUNS

US48208B3024

Valuation: JUPR NEURPAR

Chart: JUPR NEURPAR

Latest news : JUPR NEURPAR

Analysts' recommendations: JUPR NEURPAR

Press Releases: JUPR NEURPAR

Quotes and Performance

Course Extremes

Managers and Directors: JUPR NEURPAR

Latest insider transactions

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26	Andrew Cutler	Free	Director	472,222	0.9792%
6/29/26	Tomas Philipson	Free	Director	536,428	1.1124%
7/2/25	Alison Silva	Free	Chairperson	255,320	0.7713%

	2024	2025
Net sales	-	21.8K 18.85K 17.61K 16.15K 30.38K 2.07M 30.86K 207K 81.08K 1.04M 81.85K 80.06K 3.44M
Net income	-2.44M -2.11M -1.97M -1.81M -3.4M -232M -3.45M -23.12M -9.07M -116M -9.16M -8.96M -385M	-8.64M -7.48M -6.98M -6.41M -12.05M -823M -12.24M -81.93M -32.16M -412M -32.46M -31.75M -1.36B
Net Debt	-3.55M -3.07M -2.87M -2.63M -4.95M -338M -5.03M -33.66M -13.21M -169M -13.34M -13.05M -560M	1.53M 1.32M 1.24M 1.13M 2.13M 146M 2.17M 14.5M 5.69M 72.98M 5.75M 5.62M 241M